Abstract:Hematologic tumors are malignant tumors originating from the hematopoietic system, mainly including leukemia, multiple myeloma and malignant lymphoma. At present, the treatment of hematological tumors is mainly based on chemoradiotherapy combined with targeted drugs. Although the condition of patients can be improved to a certain extent at the initial stage of treatment, the resistance of tumor cells to chemotherapy or targeted therapy is the main cause of treatment failure and disease recurrence in the course of further treatment. Numerous studies have shown that metabolic reprogramming is involved in hematological tumor progression, drug resistance and tumor immunity, and tumor cells are metabolically regulated in order to generate sufficient energy supply and evade anti-tumor immune surveillance. Therefore, in-depth study of the correlation between tumor metabolic reprogramming and multi-drug resistance is of great significance for reversing tumor drug resistance and preventing tumor recurrence. This review mainly summarizes the progress of metabolic reprogramming in hematological tumors in treatment tolerance and tumor-targeted therapies targeting metabolic reprogramming.